Trump Administration Finalizes Drug Pricing Deal with Regeneron
Similar Articles
Bipartisan Support Emerges for Trump's 'Most-Favored Nation' Drug Price Plan
Trump Administration Announces New Anti-Fraud Measures in Federal Health Programs
Trump Signs Executive Order to Fast-Track Psychedelic Drug Research
Supreme Court Reviews Generic Drug 'Skinny Labeling' Case, With Major Cost Savings at Stake
FDA Grants Fast-Track Review to Three Psychedelic Drugs for Mental Health Conditions
The Trump administration has completed its series of drug pricing agreements, securing a deal with Regeneron that lowers prices for Medicaid and cash-paying patients. Combined, these deals now cover 86% of branded pharmaceuticals, though discounts largely do not apply to those with private insurance or Medicare.
Facts First
- President Trump announced a drug pricing deal with Regeneron on Thursday
- Regeneron is the 17th and final manufacturer to agree to the administration's 'most favored nation' policy
- The agreement requires lower prices for certain drugs offered to Medicaid and patients paying cash through the TrumpRx website
- The combined deals now cover 86% of branded pharmaceuticals, according to HHS chief counselor Chris Klomp
- Discounts largely do not apply to individuals with private insurance or Medicare
What Happened
President Trump announced a drug pricing deal with Regeneron on Thursday. Regeneron is the 17th and final manufacturer from a group pressured by the administration last year to commit to the 'most favored nation' policy. The agreement requires lower prices for certain drugs offered to Medicaid and to patients paying cash through the TrumpRx website. Department of Health and Human Services (HHS) chief counselor Chris Klomp stated that the combined deals now cover 86% of branded pharmaceuticals.
Why this Matters to You
If you are a Medicaid beneficiary or a cash-paying patient purchasing certain drugs through the TrumpRx website, you may see lower prices for those medications. The discounts provided in these deals largely do not apply to individuals with private insurance or Medicare, so your personal costs may not change.
What's Next
The administration's series of agreements with major manufacturers is now complete. Smaller biotechnology companies may choose to negotiate their own deals to receive exemptions from upcoming pharmaceutical tariffs.